Results 31 to 40 of about 313,286 (312)

Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma [PDF]

, 2016
Levels of plasma cell-free DNA (cfDNA) of a large series of children with classical Hodgkin lymphoma (cHL) were evaluated and analyzed at diagnosis and during chemotherapy treatment in relation with clinical characteristics.
Basso, Giuseppe, Buffardi, Salvatore, Burnelli, Roberta, Carraro, Elisa, Elia, Caterina, Farruggia, Piero, Mascarin, Maurizio, Mussolin, Lara, Pillon, Marta, Primerano, Simona, Sala, Alessandra, Vinti, Luciana   +11 more
core   +2 more sources

Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer [PDF]

, 2019
Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. Similarly, the disappearance of
Belardinilli, Francesca, Cortesi, Enrico, Gazzaniga, Paola, Gelibter, ALAIN JONATHAN, Giannini, Giuseppe, Gradilone, Angela, Loreni, Flavia, Mahdavia, Yasaman, Nicolazzo, Chiara, Raimondi, Cristina   +9 more
core   +1 more source

Evaluation of exome sequencing to estimate tumor burden in plasma. [PDF]

PLoS ONE, 2014
Accurate estimation of systemic tumor load from the blood of cancer patients has enormous potential. One avenue is to measure the presence of cell-free circulating tumor DNA in plasma.
Daniel Klevebring, Mårten Neiman, Simon Sundling, Louise Eriksson, Eva Darai Ramqvist, Fuat Celebioglu, Kamila Czene, Per Hall, Lars Egevad, Henrik Grönberg, Johan Lindberg   +10 more
doaj   +1 more source

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp

Nature Communications
Tebentafusp, a bispecific immune therapy, is the only drug that demonstrated an overall survival benefit in patients with metastatic uveal melanoma (MUM).
Manuel Rodrigues, Toulsie Ramtohul, Aurore Rampanou, José Luis Sandoval, Alexandre Houy, Vincent Servois, Léah Mailly-Giacchetti, Gaelle Pierron, Anne Vincent-Salomon, Nathalie Cassoux, Pascale Mariani, Caroline Dutriaux, Marc Pracht, Thomas Ryckewaert, Jean-Emmanuel Kurtz, Sergio Roman-Roman, Sophie Piperno-Neumann, François-Clément Bidard, Marc-Henri Stern, Shufang Renault   +19 more
doaj   +1 more source

Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA

Molecular Cancer, 2019
Hepatocellular carcinoma (HCC) is one of the most common cancers and a leading cause of death worldwide. Due to latent liver disease, late diagnosis, and nonresponse to systemic treatments, surgical resection and/or biopsy specimens are still generally ...
Qianwei Ye, Sunbin Ling, Shusen Zheng, Xiao Xu   +3 more
doaj   +1 more source

Liquid-based biomarkers in breast cancer: looking beyond the blood

Journal of Translational Medicine, 2023
In recent decades, using circulating tumor cell (CTC), circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), exosomes and etc. as liquid biomarkers has received enormous attention in various tumors, including breast cancer (BC).
You Shuai, Zhonghua Ma, Jie Ju, Tong Wei, Songlin Gao, Yikun Kang, Zixuan Yang, Xue Wang, Jian Yue, Peng Yuan   +9 more
doaj   +1 more source

Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post‐Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background We describe clinical and biologic characteristics of neuroblastoma in older children, adolescents, and young adults (OCAYA); describe survival outcomes in the post‐immunotherapy era; and identify if there is an age cut‐off that best discriminates outcomes.
Rebecca J. Deyell, Kavitha Srivatsa, Paola Angelini, Pei‐Chi Kao, Brady Payne, Arlene Naranjo, Sveva Castelli, Miho Kato, Miki Ohira, Ulriche Pöetschger, Yaël Mossé, Lucas Moreno, Meredith S. Irwin, Ramya Ramanujachar, Wendy B. London   +14 more
wiley   +1 more source

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. [PDF]

, 2017
A challenge in precision medicine requires identification of actionable driver mutations. Critical to such effort is the deployment of sensitive and well-validated assays for mutation detection.
Ali, Siraj, Bergsland, Emily K, Bivona, Trever G, Damato, Bertil, Fogh, Shannon, Miller, Vincent A, Urisman, Anatoly, Wang, Victoria E, Wolfe, John, Young, Lauren   +9 more
core   +1 more source

Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA

Molecular Oncology, 2019
Reliable biomarkers are required to evaluate and manage pancreatic ductal adenocarcinoma. Circulating tumor cells and circulating tumor DNA are shed into blood and can be relatively easily obtained from minimally invasive liquid biopsies for serial ...
Jee‐Soo Lee, Sung Sup Park, Young Kyung Lee, Jeffrey A. Norton, Stefanie S. Jeffrey   +4 more
doaj   +1 more source

Hematopoietic (stem) cells—The elixir of life?

FEBS Letters, EarlyView.
The aging of HSCs (hematopoietic stem cells) and the blood system leads to the decline of other organs. Rejuvenating aged HSCs improves the function of the blood system, slowing the aging of the heart, kidney, brain, and liver, and the occurrence of age‐related diseases.
Emilie L. Cerezo, Jonah Anderson, Emilie Dinh Vedrenne, Noël Yeh Martín, Jette Lengefeld   +4 more
wiley   +1 more source